Enter your keyword

Efficiently Creating Value with Innovative Science

Press Releases

Date Title and Summary Additional Formats
Toggle Summary OXiGENE Sets Conference Call and Webcast for Fourth Quarter and Full-Year 2004 Results
OXiGENE Sets Conference Call and Webcast for Fourth Quarter and Full-Year 2004 Results WALTHAM, Mass.--(BUSINESS WIRE)--Feb. 9, 2005--OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN) invites the public to listen to a live audio webcast of the Company's fourth quarter and full-year 2004 financial results
View HTML
Toggle Summary OXiGENE's CA4P Demonstrates Anti-tumor Activity in Preclinical Retinoblastoma Model- Study Published in Investigative Ophthalmology & Visual Science -
OXiGENE's CA4P Demonstrates Anti-tumor Activity in Preclinical Retinoblastoma Model- Study Published in Investigative Ophthalmology & Visual Science - WALTHAM, Mass.--(BUSINESS WIRE)--Feb. 4, 2005--OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN) announced today the publication of a preclinical study using
View HTML
Toggle Summary OXiGENE Announces Corporate Goals for 2005: Company Plans to Move CA4P into Later-stage Clinical Studies in Two Cancer Indications in 2005
OXiGENE Announces Corporate Goals for 2005: Company Plans to Move CA4P into Later-stage Clinical Studies in Two Cancer Indications in 2005 WALTHAM, Mass.--(BUSINESS WIRE)--Jan. 7, 2005--OXiGENE, Inc. (Nasdaq: OXGN, XSSE: OXGN), developing novel small-molecule therapeutics to treat cancer and
View HTML